Table 1.
Anthropometric, clinical parameters and VAT and SAT CDO1 mRNA levels according to obesity in cohort 1.
| Non-obese | Obese | P-value | |
|---|---|---|---|
| N | 112 | 187 | |
| Sex (men/women) | 15/97 | 39/148 | |
| Age (years) | 47.08 ± 11.4 | 47.8 ± 10.6 | 0.5 |
| BMI (kg/m2) | 24.6 ± 3.1 | 42.5 ± 7.2 | <0.0001 |
| Fasting glucose (mg/dl)a | 90 (85-97.7) | 96 (88-113) | 0.03 |
| HbA1c (%) | 5.5 ± 0.68 | 5.9 ± 1.02 | <0.0001 |
| HDL-cholesterol (mg/dl) | 61.57 ± 16.1 | 50.1 ± 13.9 | <0.0001 |
| Fasting triglycerides (mg/dl)a | 86.5 (58.5-114.2) | 117 (82.2-158.7) | <0.0001 |
| hsCRP (mg/dl)a | 0.35 (0.11-0.68) | 0.73 (0.34-1.45) | <0.0001 |
| VAT CDO1 (RU)a | 0.20 (0.14-0.31) | 0.21 (0.13-0.29) | 0.7 |
| SAT CDO1 (RU)a | 0.25 (0.19-0.31) | 0.23 (0.17-0.28) | 0.07 |
a
Median and interquartile range; R.U., relative gene expression units to PPIA (endogenous control) gene expression.